Compare Repligen Corporation Common Stock (RGEN) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Block Inc — how do they compare? Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B), while Block Inc trades at $75.39 (market cap $46.18B). The key difference: Block Inc is far larger — about 4.1× Repligen Corporation Common Stock's market cap, and Block Inc is more actively traded (4,211,951 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Block Inc for 78 Days on average.
| RGEN | XYZ | |
|---|---|---|
Market Cap | $11.14B | $46.18B |
Volume | 1,259,263 | 4,211,951 |
Sector | Health | Technology |
52-Week High | $194.57 | $84.85 |
52-Week Low | $102.87 | $49.04 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $11.02B | $41.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XYZ trades at $75.87, down 1.21% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, though net income margin is thin at 1.43%. The company shows robust revenue growth, reaching $24.19B in 2025, and is expanding through partnerships like Apple and Workday. Cash flow from operations is strong at $2.58B, but net cash flow was negative $749M in 2025 due to heavy investing.
Outlook is positive with a consensus price target of $97.47, implying 28% upside. Key opportunities include continued earnings beats and strategic expansions, but risks include high P/E of 137.25, insider selling, and competitive pressures in fintech. The stock's valuation relies on sustained growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
